New antibody drug aims to quiet artery inflammation in heart disease patients
NCT ID NCT06572267
First seen Jan 27, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This early study tests a drug called meplazumab in 18 people with stable coronary artery disease. The drug targets a protein linked to inflammation that may worsen artery plaques. Researchers will use CT scans and blood tests to see if the drug reduces inflammation and plaque buildup over time. The goal is to find a safe dose and check for any early signs of benefit.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CORONARY ARTERY DISEASE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ling Tao
RECRUITINGXi'an, Shannxi, 710032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.